No Data
No Data
Recursion Pharmaceuticals Call Volume Above Normal and Directionally Bullish
Recursion Pharmaceuticals (RXRX) Bold Acquisition Makes It a Leader in AI Drug Discovery
Recursion Announces First Patient Dosed In Phase 1/2 Clinical Study Of REC-1245, A RBM39 Degrader For Biomarker-Enriched Solid Tumors And Lymphoma
Express News | Recursion Announces First Patient Dosed in Phase 1/2 Clinical Study of REC-1245, a Potential First-in-Class, Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
Follow Nvidia's Lead in Investing in Small-Cap AI Stocks
Nvidia Bought 6 Artificial Intelligence (AI) Stocks, but This 1 Has Soared the Most
D3VIN : why is this such a good bet?
Big bull Salvekar OP D3VIN : Monopoly, launching own LLMs, Pharma is always needed so is AI so you get bet of all
Mountain Money : bus looks crashed
Big bull Salvekar OP Mountain Money : Look last 3 days 30% up today cooling down :) so opportunity I just post opportunities
D3VIN Big bull Salvekar OP : I'll buy a few hundred shares, hope you are right.
View more comments...